Literature DB >> 24985971

The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis.

G G Sun1, Y D Wang, Y J Cheng, W N Hu.   

Abstract

To determine the expression and function of B cell translocation gene 1 (BTG1) in nasopharyngeal carcinoma. Nasopharyngeal samples were taken from cancer lesions (n = 75) and adjacent normal tissue (n = 33) in nasopharyngeal cancer patients immediately after endoscopic biopsy. BTG1 expression was determined by immunohistochemistry and Western blotting. The effect of BTG1 overexpression was examined in vitro utilizing a human nasopharyngeal cancer cell line CNE2 stably transfected with a recombinant lentivirus (LeBTG1 cells) and compared to empty vector-transfected controls (LeEmpty). BTG1 overexpression was verified by real-time reverse transcriptase polymerase chain reaction and Western blot. The expression of proteins involved in cell cycle regulation (cyclin D1), apoptosis (Bcl-2) and cell migration (MMP-9) in LeBTG1 cells were analyzed by Western blot. The effect of BTG1 overexpression on cell viability and proliferation was assessed by an MTT assay in LeBTG1 and LeEmpty cells. Flow cytometric analyses were used to evaluate the effect of BTG1 expression on cell cycle distribution and apoptosis. The migration and invasion potential of LeBTG1 cells was examined by plating cells in Matrigel-coated chambers. BTG1 protein expression was significantly lower in nasopharyngeal cancer tissue biopsies than normal tissue as measured by immunohistochemistry (36.0 vs. 81.8 % of tissues; P < 0.05) and Western blotting (0.221 ± 0.019 vs. 0.652 ± 0.055; P < 0.05). Decreased expression of BTG1 was significantly correlated with nasopharyngeal cancer tumor stage, lymph node metastasis, clinical stage and pathologic differentiation (P < 0.05), as well as with reduced overall five-year survival rates compared to patients with higher expression levels (31.2 vs. 70.2 %; P < 0.05). In vitro analyses revealed that LeBTG1 cells had a reduced survival fraction compared to control LeEmpty cells, with higher rates of apoptosis (9.3 ± 0.7 vs. 2.3 ± 0.3 %; P < 0.05). The proportion of LeBTG1 cells in G0/G1 stage and S phase was also significantly different from LeEmpty cells (82.6 ± 3.8 and 10.1 ± 1.0 %, vs. 62.2 ± 2.4 and 28.9 ± 2.0 %, respectively; Ps < 0.05), and the migration and invasion of LeBTG1 cells was significantly impaired with respect to LeEmpty cells (96.0 ± 13.0 and 91.0 ± 11.0 vs. 158.0 ± 17.0 and 142.0 ± 15.0, respectively; Ps < 0.05). These effects were accompanied by decreased protein expression of cyclin D1, Bcl-2 and MMP-9 in LeBTG1 cells (0.231 ± 0.021, 0.413 ± 0.046, 0.131 ± 0.011, respectively) compared to control LeEmpty cells (0.636 ± 0.067, 0.821 ± 0.083, 0.451 ± 0.041, respectively; Ps < 0.05). Reduced BTG1 expression is associated with increased disease severity, suggesting it is a negative regulator of nasopharyngeal cancer and can serve as a prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24985971     DOI: 10.1007/s11033-014-3475-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  BTG gene expression in the p53-dependent and -independent cellular response to DNA damage.

Authors:  U Cortes; C Moyret-Lalle; N Falette; C Duriez; F E Ghissassi; C Barnas; A P Morel; P Hainaut; J P Magaud; A Puisieux
Journal:  Mol Carcinog       Date:  2000-02       Impact factor: 4.784

2.  Apoptosis. Life and death decisions.

Authors:  Donald W Nicholson; Nancy A Thornberry
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

Review 3.  Metabolism in physiological cell proliferation and differentiation.

Authors:  Michalis Agathocleous; William A Harris
Journal:  Trends Cell Biol       Date:  2013-06-04       Impact factor: 20.808

4.  Western blot of proteins from Coomassie-stained polyacrylamide gels.

Authors:  V Ranganathan; P K De
Journal:  Anal Biochem       Date:  1996-02-01       Impact factor: 3.365

Review 5.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

Review 6.  The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair?

Authors:  F Tirone
Journal:  J Cell Physiol       Date:  2001-05       Impact factor: 6.384

7.  Exploration of target molecules for prostate cancer gene therapy.

Authors:  Kazuhiro Suzuki; Kiminori Nakamura; Kazunori Kato; Hirofumi Hamada; Taiji Tsukamoto
Journal:  Prostate       Date:  2007-08-01       Impact factor: 4.104

Review 8.  The mammalian anti-proliferative BTG/Tob protein family.

Authors:  G Sebastiaan Winkler
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

Review 9.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

10.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

View more
  9 in total

1.  Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.

Authors:  Xiu-Qiong Chen; Fan-Qiao Meng; Hua Xiong; Ya-Li Wang; Wen-Hua Tang; Yan-Mei Zou
Journal:  Curr Med Sci       Date:  2020-03-13

2.  MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.

Authors:  Yong-Hao Nan; Jun Wang; Yao Wang; Peng-Hao Sun; Yu-Ping Han; Li Fan; Kai-Chen Wang; Fu-Jun Shen; Wei-Hua Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma.

Authors:  Yibing Li; Jianing Huo; Junjian He; Yunzheng Zhang; Xiaoxin Ma
Journal:  Cancer Cell Int       Date:  2020-10-07       Impact factor: 5.722

4.  BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.

Authors:  Hua-chuan Zheng; Jing Li; Dao-fu Shen; Xue-feng Yang; Shuang Zhao; Ya-zhou Wu; Yasuo Takano; Hong-zhi Sun; Rong-jian Su; Jun-sheng Luo; Wen-feng Gou
Journal:  Oncotarget       Date:  2015-08-14

5.  B-cell translocation gene 1 is downregulated by promoter methylation in ovarian carcinoma.

Authors:  Ji-Ye Kim; Sung-Im Do; Go Eun Bae; Hyun-Soo Kim
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

6.  BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial-Mesenchymal Transition.

Authors:  Shuang Zhao; Hang Xue; Chang-Lai Hao; Hua-Mao Jiang; Hua-Chuan Zheng
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

7.  Exosomal microRNA-301a-3p promotes the proliferation and invasion of nasopharyngeal carcinoma cells by targeting BTG1 mRNA.

Authors:  Qiang Cheng; Qiang Li; Lingen Xu; Hui Jiang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

8.  Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Authors:  Laurensia Yuniati; Laurens T van der Meer; Esther Tijchon; Dorette van Ingen Schenau; Liesbeth van Emst; Marloes Levers; Sander A L Palit; Caroline Rodenbach; Geert Poelmans; Peter M Hoogerbrugge; Jixiu Shan; Michael S Kilberg; Blanca Scheijen; Frank N van Leeuwen
Journal:  Oncotarget       Date:  2016-01-19

9.  BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers.

Authors:  Shuang Zhao; Shu-Rui Chen; Xue-Feng Yang; Dao-Fu Shen; Yasuo Takano; Rong-Jian Su; Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2017-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.